Alexza Pharmaceuticals Inc.
|
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALXA: effective 9:15 A.M. today, for every 1 share of ALXA that was not tendered, shareholders will receive a) $0.90 per share & b) 1 contractual contingent value right ("CVR") which represents the right to receive a pro-rata share of up to four payment categories in an aggregate maximum amount of $32.8 million if certain licensing payments and revenue milestones are achieved; see the company's SEC filings for additional details.
FINRA deleted symbol:
http://otce.finra.org/DLDeletions
ALXA delisted from the Nasdaq to the OTC.:
http://otce.finra.org/DLAdditions
The initial, unbinding letter of intent filed (I believe) on 2/24 took a couple days to really pop the price from high .20's up to low 60's, right? Then it took another three days to reach it's peak.
Without a firm price target, I think news for Alexza takes a little time to catch on and the price to reflect it. Maybe not as long since this seals up that initial deal that (IMO) more investors would be aware of.
That puts me at 2-3 more days to trend up, adjusting the exit point throughout the first two days. Ideally you find a peak on the third day for short-term.
How wrong am I?
so what happens after this?
New 8K MERGER APPROVED! Ferrer will buy up float in cash at .90
In addition to the upfront cash payment, Alexza stockholders will be granted contingent value rights to receive cash payments in four payment categories if specified milestones are achieved following the closing.
news is out. disappointing. enough with the pumping. stock will be back to 20s soon.
With good news we could see $1 go Alxa
Holding at .72 now its time for the push
Alexza Pharmaceuticals Incorporated to release 2015 earnings today.
Investor Conference Call: Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA)
Posted by: James Smith in Health CareMarch 28, 2016 0 48 Views
Shares of Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) ended Thursday session in green amid volatile trading. The shares closed up +0.179 points or 31.96% at $0.739 with261,598.00 shares getting traded. Post opening the session at $0.58, the shares hit an intraday low of $0.56 and an intraday high of $0.75 and the price vacillated in this range throughout the day. The 52-week high of (ALXA) is $2.12 and the 52-week low is $0.22. The company has a market cap of $14.86 million and the numbers of outstanding shares have been calculated to be 19.57 million shares. Historically, the volatility of this stock is about 17.64% a week and 22.25% a month.
Alexza Pharmaceuticals, Inc. (ALXA) announced that it will report results for its fiscal quarter and year ended December 31, 2015 on Monday, March 28, 2016 following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
To access the webcast via the Internet, go to www.alexza.com, under the “Investors” link. Please log onto the webcast prior to the start of the call to ensure time for any software downloads that may be required to participate in the webcast.
Link:
http://sharemarketupdates.com/investor-conference-call-alexza-pharmaceuticals-inc-nasdaqalxa/
Support building up again that's great could close @ .91 today
No bad lets shake out the flippers
Let it fly people we have news coming today
i think we can expect some news on monday after hours in regards to the buyout offer. fins will be released aswell + conference call.
wtf happened? nice candle this afternoon
no specific prize yet but a LOI to acquire all outstanding shares.
what do you think shareholders will accept as a buyout prize?
$1? $2? $3? $4? $5?
what buyout prize will shareholders accept? opinions?
* * $ALXA Video Chart 02-29-16 * *
Link to Video - click here to watch the technical chart video
How do you like that carl?
Huge move up!!! Maybe a sign of a run!!! Go ALXA!!! GLTA
Any ideas to where this is heading?
Very nice!
Looking for pull back !
Coooooovvvver your shorts u are in trouble now
Will see .01 now
Even more WRONG
Sadness. Not much to take this down over the last couple weeks. No interest.
Very small float, we should see at least $2.50 in the coming days
Wish I was able to short from $1.34 pre market down to the ninties too, but my broker doesn't allow shorts under $5
long or short?
Followers
|
57
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3195
|
Created
|
06/29/07
|
Type
|
Free
|
Moderators |
Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals is a rapidly emerging pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS conditions. All of our product candidates are based on our proprietary technology, the Staccato® system. The Staccato system vaporizes excipient-free drugs to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the ideal particle size of the aerosol, the pure drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous (IV) administration but with greater ease, patient comfort and convenience.Alexza's lead program is ADASUVE™ (Staccato loxapine or AZ-004), being developed for the acute treatment of agitation in patients with schizophrenia or bipolar disease. During 2011, Alexza resubmitted the ADASUVE NDA and the ADASUVE MAA in Europe. Alexza has a U.S. PDUFA goal date for ADASUVE of February 4, 2012.Staccato nicotine (Preclinical) |
Thomas B. King President, Chief Executive Officer Thomas B. King has served as our President, Chief Executive Officer and a member of our Board since June 2003. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development company. From January 1994 to February 2001, Mr. King held various senior executive positions, including President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors at Anesta Corporation, a publicly traded pharmaceutical company, until it was acquired by Cephalon, Inc., a publicly traded biopharmaceutical company. Mr. King received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College. |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |